Advertisement
Advertisement
SABS
SAB Biotherapeutics, Inc. Common Stock
3.90
USDSponsored
+0.05
+1.30%
Aug 07, 15:58 UTC -4
Closed
After-Market
3.87
-0.03
-0.77%
SABS Earnings Reports
Positive Surprise Ratio
SABS beat 12 of 20 last estimates.
60%
Next Report
Date of Next Report
Nov 11, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.29
Implied change from Q2 26 (Revenue/ EPS)
--
/+3.57%
Implied change from Q3 25 (Revenue/ EPS)
--
/+93.33%
SAB Biotherapeutics, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, SABS reported earnings of -0.28 USD per share (EPS) for Q2 26, beating the estimate of -0.29 USD, resulting in a 5.15% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +2.12% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 8 analysts forecast an EPS of -0.29 USD, with revenue projected to reach -- USD, implying an increase of 3.57% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
FAQ
What were SAB Biotherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, SAB Biotherapeutics, Inc. Common Stock reported EPS of -$0.28, beating estimates by 5.15%, and revenue of $0.00, 0% as expectations.
How did the market react to SAB Biotherapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 2.12%, changed from $3.77 before the earnings release to $3.85 the day after.
When is SAB Biotherapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 11, 2026.
What are the forecasts for SAB Biotherapeutics, Inc. Common Stock's next earnings report?
Based on 8
analysts, SAB Biotherapeutics, Inc. Common Stock is expected to report EPS of -$0.29 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement